Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing.

Immunity·2026
Same author

A distinct E dimer epitope underlies selective recognition by a protective human West Nile virus antibody.

EMBO reports·2026
Same author

Asymmetric structural transitions in the icosahedral organization of Eastern equine encephalitis virus.

Nature communications·2026
Same author

Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge.

The Journal of clinical investigation·2026
Same author

Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.

Nature microbiology·2026
Same author

Structural basis for recognition of Rift Valley fever virus Gn protein by a human neutralizing monoclonal antibody with a kappa light chain.

PLoS pathogens·2026

Related Experiment Video

Updated: Jul 4, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies.

Xiaocong Yu1, Patricia A McGraw, Frances S House

  • 1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Journal of Immunological Methods
|June 3, 2008
PubMed
Summary

Researchers developed an efficient electrofusion technique to create human hybridomas. These hybridomas produce virus-specific monoclonal antibodies for diagnosing and treating respiratory infections like RSV and influenza.

More Related Videos

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Related Experiment Videos

Last Updated: Jul 4, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Area of Science:

  • Immunotechnology
  • Virology
  • Cell Biology

Background:

  • Hybridoma technology is crucial for producing monoclonal antibodies.
  • Generating human hybridomas for clinical applications remains challenging.
  • Existing methods for human hybridoma generation have limitations in efficiency.

Purpose of the Study:

  • To develop and optimize a hybridoma-based technology for generating human hybridomas.
  • To produce human hybridomas secreting virus-specific monoclonal antibodies for diagnosis and therapy.
  • To improve the efficiency of human hybridoma generation using electrofusion.

Main Methods:

  • A novel electrofusion protocol was developed for fusing Epstein-Barr virus (EBV)-transformed human B cells with myeloma partners.
  • Seven myeloma cell lines were tested, with HMMA 2.5 showing the highest efficiency.
  • Optimization involved pre- and post-fusion cell treatments, cell ratios, and fusion medium adjustments.

Main Results:

  • The optimized electrofusion protocol achieved a fusion efficiency of 0.43%.
  • This efficiency significantly surpasses previous polyethylene glycol (PEG)-based and other electrofusion methods.
  • Functional human monoclonal antibodies targeting respiratory syncytial virus (RSV) and an influenza H3N2 strain were generated.

Conclusions:

  • An efficient and routine approach for generating human hybridomas secreting functional human virus-specific monoclonal antibodies has been established.
  • The developed technology offers a promising avenue for producing diagnostic and therapeutic antibodies.
  • This advancement has implications for combating respiratory viral pathogens.